We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of YH0618 soup on chemotherapy-induced toxicity in patients with cancer who have completed chemotherapy: study protocol for a randomized controlled trial.
- Authors
Jie-shu You; Jian-ping Chen; Chan, Jessie S.M.; Ho-fun Lee; Mei-kuen Wong; Wing-Fai Yeung; Li-xing Lao; You, Jie-Shu; Chen, Jian-Ping; Lee, Ho-Fun; Wong, Mei-Kuen; Yeung, Wing-Fai; Lao, Li-Xing
- Abstract
<bold>Background: </bold>The incidence of cancer has been staying at a high level worldwide in recent years. With advances in cancer diagnosis and therapy strategy, the survival rate of patients with cancer has been increasing, but the side effects of these treatments, especially chemotherapy, are obvious even when the chemotherapy ceases. YH0618, a prescription, has showed efficacy in reducing chemotherapy-induced toxicity through long clinical practice. However, there is no scientific research exploring the effects of YH0618 in patients with cancer. Therefore, using a randomized controlled trial, this study will explore the efficacy of YH0618 on ameliorating chemotherapy-induced toxicity including dermatologic toxicity, myelosuppression, hepatotoxicity and nephrotoxicity and improving fatigue in cancer patients who have completed chemotherapy.<bold>Methods/design: </bold>This is a prospective assessor-blinded, parallel, randomized controlled trial. Patients with cancer at any stage who have completed chemotherapy within two weeks will be randomly divided into group A (YH0618) and group B (wait-list) using a 1:1 allocation ratio. The chemotherapeutic agents include taxanes or anthracyclines. Subjects assigned to group A will receive YH0618 soup 6 days a week for 6 weeks and uncontrolled follow-up for 6 weeks, while group B are required to wait for 6 weeks before receiving YH0618 intervention. The primary outcome of this study is the incidence of protocol-specified grade ≥2 dermatologic toxicities graded by NCI CTCAE Chinese version 4.0 and changes of fingernail color, face skin color and tongue color evaluated by the L*a*b system within 6 weeks. There are some secondary outcomes associated with dermatologic toxicity including fatigue and clinical objective examination.<bold>Discussion: </bold>There are few scientific and safe methods in ameliorating chemotherapy-induced toxicity. The proposed study may provide direct and convincing evidence to support YH0618 as an adjuvant treatment for reducing chemotherapy-induced toxicity, which could be introduced into clinical settings.<bold>Trial Registration: </bold>Chinese Clinical Trial Registry: ChiCTR-IOR-15006486 . Registered on 21 May 2015.
- Subjects
HONG Kong (China); CHEMOTHERAPY complications; DERMATOTOXICOLOGY; HERBAL medicine; CHINESE medicine; HUMAN skin color; FATIGUE (Physiology); ADVERSE health care events; RANDOMIZED controlled trials; PREVENTION; PREVENTION of drug side effects; FATIGUE prevention; KIDNEY disease prevention; ANTINEOPLASTIC agents; BONE marrow diseases; COMPARATIVE studies; DRUG eruptions; DRUG side effects; EXPERIMENTAL design; KIDNEY diseases; LONGITUDINAL method; RESEARCH methodology; MEDICAL cooperation; RESEARCH protocols; RESEARCH; SOYFOODS; TIME; TUMORS; EVALUATION research; TREATMENT effectiveness
- Publication
Trials, 2016, Vol 17, p1
- ISSN
1745-6215
- Publication type
journal article
- DOI
10.1186/s13063-016-1443-9